The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
T-Cell Exhaustion in CLL: Allogeneic CAR T Trial Reaching Patients With Unmet Need
April 30th 2024"Off the shelf" CAR T-cell therapies could offer a solution in chronic lymphocytic leukemia, where T-cell exhaustion creates treatment challenges. This article will appear in the May 2024 issue of Evidence-Based Oncology.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Real-World Study Confirms Nivolumab Plus Ipilimumab Safety in Advanced NSCLC
March 8th 2024A real-world study confirmed that the rate of adverse events associated with first-line nivolumab plus iplimumab therapy was in line with the safety profiles of other immuno-oncology and chemotherapy combination regimens.
Read More
ASH Abstracts Show PRO Improvements, Long-Term Efficacy of Cilta-Cel in MM
December 24th 2023Data presented at the 2023 American Society of Hematology (ASH) Annual Meeting and Exposition highlighted improvements in patient-reported outcomes (PROs) with ciltacabtagene autoleucel (cilta-cel) in multiple myeloma (MM).
Read More
FDA Approves Enfortumab Vedotin Plus Pembrolizumab for Locally Advanced or Metastatic Bladder Cancer
December 18th 2023In the phase 3 EV-302/KEYNOTE-A39 clinical trial, the antibody-drug conjugate enfortumab vedotin plus PD-1 inhibitor pembrolizumab nearly doubled both median overall survival and progression-free survival compared with chemotherapy.
Read More
ICYMI: Highlights From ESMO Congress 2023
December 15th 2023Our most-read coverage from the 2023 European Society for Medical Oncology (ESMO) Congress included potentially practice-changing findings across a range of cancer types, including lung cancer, breast cancer, and urothelial carcinoma.
Read More
Second-Line Axi-Cel Prolongs Survival Over Standard of Care in Elderly Patients With R/R LBCL
December 11th 2023The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.
Read More
Dr Guru Sonpavde: Nivolumab Plus Gemcitabine-Cisplatin Holds Promise in Urothelial Cancer
November 30th 2023Urothelial carcinoma has long been treated with chemotherapy as the frontline standard of care, but recent trial results in the space have potential to add to the treatment armamentarium and improve outcomes for the first time in decades.
Read More
The FDA has approved pembrolizumab (Keytruda) in combination with fluoropyrimidine- and platinum-containing chemotherapy for the first-line treatment of adult patients with locally advanced unresectable or metastatic, HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Read More
FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma
November 9th 2023Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.
Read More
Maintenance Durvalumab Plus Olaparib Improves PFS in Advanced or Recurrent Endometrial Cancer
November 1st 2023The addition of durvalumab to first-line chemotherapy, followed by maintenance treatment with durvalumab plus olaparib significantly improved progression-free survival in patients with newly diagnosed advanced or recurrent endometrial cancer, according to data from the phase 3 DUO-E/GOG-3041/ENGOT-EN10 trial.
Read More